Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
Gemcitabine and Cisplatin With Erlotinib in Hepatocellular Carcinoma (HCC) and Biliary Tree Cancer (BTC) (Intra- and Extra-hepatic Cholangiocarcinoma, Bile Duct Cancer, Adenocarcinoma of the Ampulla of Vater and Gallbladder Carcinoma)
Sponsor: New Mexico Cancer Research Alliance
Listed as NCT00832637, this PHASE2 trial focuses on Bile Duct Cancer and Cholangiocarcinoma of the Extrahepatic Bile Duct and remains terminated or withdrawn. Sponsored by New Mexico Cancer Research Alliance, it has been updated 11 times since 2007, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
11 versions recorded-
Jan 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Jan 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
-
Jul 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Terminated PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Dec 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Aug 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- New Mexico Cancer Research Alliance
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Albuquerque, United States
- • San Francisco, United States